Merck snags priority review for Prevnar 13 rival — just one month after Pfizer sent its follow-on to the FDA

Almost a decade after Prevnar 13 was approved — going on to become Pfizer’s best-selling product — Merck is one step away from having a rival vaccine to offer.

The FDA is tucking V114, the 15-valent pneumococcal conjugate vaccine, into its priority review line, meaning we’ll know by July whether Merck can finally complete the years-long journey to dethrone Prevnar 13.